Cyclo Therapeutics Stock Forum

$Cyclo Therapeutics (CYTH.US)$
Item 1.01.
Entry into a Material Definitive Agreement.
 
On December 5, 2024, Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), entered into a Sixth Amended and Restated Note Purchase Agreement (the “Agreement”) with Rafael Holdings, Inc., a Delaware corporation (“Rafael”), pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $1,000,000.00 (the “Note”) to Rafael. The Agreemen...

$Cyclo Therapeutics (CYTH.US)$
GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2024 and provided a business update...

$Cyclo Therapeutics (CYTH.US)$
EditorLina Guerrero
Published 10/08/2024, 05:25 PM
Cyclo Therapeutics, Inc., a biopharmaceutical company, announced today that it has entered into a material definitive agreement with Rafael Holdings, Inc., securing a new convertible promissory note worth $3 million. This agreement amends previous arrangements, extending the maturity date of existing notes and aligning them with the new note's terms.
On ...

$Cyclo Therapeutics (CYTH.US)$
Cyclo Therapeutics secures $3 million convertible note financing By Investing.com

$Cyclo Therapeutics (CYTH.US)$
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data From Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (Npc1)
https://www.moomoo.com/t/news/flash/19100681/3FJnV3zjzb

$Cyclo Therapeutics (CYTH.US)$
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
Cyclo Therapeutics (Nasdaq: CYTH) presented encouraging preliminary safety data from its ongoing pivotal Phase 3 study (TransportNPC™) and substudy evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) at the SSIEM Annual Symposium 2024. The TransportNPC™ study, with 104 enrolled pa...